%0 Journal Article
%T An¨¢lisis de impacto presupuestal de la introducci¨®n de fingolimod en el tratamiento de esclerosis m¨²ltiple en Colombia: a budget impact analysis
%A Rosselli
%A Diego
%A Guillermo Ariza
%A Juan
%A Acosta
%A Tatiana
%A Rueda
%A Juan David
%J Acta Neurol¨®gica Colombiana
%D 2012
%I Scientific Electronic Library Online
%X introduction: multiple sclerosis (ms) is associated with long-term disability and significant social impact. first-line disease modifying treatments for ms (interferons and glatiramer acetate) have moderate efficacy and must be administered in daily or weekly injections. the introduction of fingolimod, a molecule with superior efficacy in reducing ms relapses compared to interferon-beta 1a justifies a budget impact analysis from a colombian health system perspective. objetives: to develop a budget impact analysis, for years 2012 to 2016, of the introduction of fingolimod in the colombian health system. materials and methods: using the perspective of the colombian health system, we designed a budget impact model to determine the effect that the introduction of fingolimod for patients with relapsing-remitting ms would have on the resources of the health system. clinical data and prevalence were obtained from published literature, costs were collected from local sources. a monte carlo simulation was done as part of the sensitivity analysis. exchange rate used was 2,565 pesos per euro (july 2011). results: total annual net costs (2012-2016) for the scenario without fingolimod were, in million euros, ?8.17, ??8.69, ?9.11, ?9.62, and ?10.13. in the fingolimod scenario net costs were: ?8.19, ?8.74, ?9.16, ?9.71 and ?10.29. on the other hand, fingolimod was associated with 91 relapses averted in this five-year period. monte carlo simulation does not show relevant differences in costs between both scenarios. conclusion: under these assumptions, the introduction of fingolimod in colombian health care system does not imply a significant budget impact but represents an important reduction in the number ms relapses.
%K budget impact
%K evaluation studios
%K fingolimod
%K health evaluation
%K multiple sclerosis relapsing remitting.
%U http://www.scielo.org.co/scielo.php?script=sci_abstract&pid=S0120-87482012000100002&lng=en&nrm=iso&tlng=en